Stereotactic body radiation therapy for colorectal liver metastases

References

• Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Investig Med. 2017;65(2):311–315.
   PubMed Web of Science ®Google Scholar
• Valderrama-Trevino AI, Barrera-Mera B, Ceballos-Villalva JC, et al. Hepatic metastasis from colorectal cancer. Euroasian J Hepatogastroenterol. 2017;7(2):166–175.
   PubMedGoogle Scholar
• Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.
   PubMed Web of Science ®Google Scholar
• Xu F, Tang B, Jin TQ, et al. Current status of surgical treatment of colorectal liver metastases. World J Clin Cases. 2018;6(14):716–734.
   PubMed Web of Science ®Google Scholar
• Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.
   PubMedGoogle Scholar
• Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225–1239.
   PubMed Web of Science ®Google Scholar
• Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27(11):1829–1835.
   PubMed Web of Science ®Google Scholar
• Martin J, Petrillo A, Smyth EC, et al. Colorectal liver metastases: current management and future perspectives. World J Clin Oncol. 2020;11(10):761–808.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336–342.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Comito T, Clerici E, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol. 2018;13(1):234.
   PubMed Web of Science ®Google Scholar
• Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–4069.
   PubMed Web of Science ®Google Scholar
• Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Front Radiat Ther Oncol. 2004;38:100–105.
   PubMedGoogle Scholar
• Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–830.
   PubMed Web of Science ®Google Scholar
• Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–1591.
   PubMed Web of Science ®Google Scholar
• Mendez Romero A, Wunderink W, van Os RM, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys. 2008;70(5):1447–1452.
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–1578.
   PubMed Web of Science ®Google Scholar
• Gandhi SJ, Liang X, Ding X, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: photons versus protons. Pract Radiat Oncol. 2015;5(4):209–218.
   PubMedGoogle Scholar
• van der Pool AE, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97(3):377–382.
   PubMed Web of Science ®Google Scholar
• Vernaleone M, Bonomo P, Di Cataldo V, et al. Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience. Radiol Med. 2019;124(9):870–876.
   PubMed Web of Science ®Google Scholar
• Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol. 2020;21(2):e74–e82.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810–821.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005;15(4):279–283.
   PubMed Web of Science ®Google Scholar
• Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3):S94–S100.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95(5):1399–1404.
   PubMed Web of Science ®Google Scholar
• Andratschke N, Alheid H, Allgäuer M, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18(1):283.
   PubMed Web of Science ®Google Scholar
• Berber B, Ibarra R, Snyder L, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB. 2013;15(11):851–857.
   PubMed Web of Science ®Google Scholar
• Clerici E, Comito T, Franzese C, et al. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. Strahlenther Onkol. 2020;196(4):325–333.
   PubMed Web of Science ®Google Scholar
• Doi H, Uemoto K, Suzuki O, et al. Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer. Oncol Lett. 2017;14(1):453–460.
   PubMed Web of Science ®Google Scholar
• Goodman BD, Mannina EM, Althouse SK, et al. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6(2):86–95.
   PubMed Web of Science ®Google Scholar
• Joo JH, Park JH, Kim JC, et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–883.
   PubMed Web of Science ®Google Scholar
• Kim M-S, Kang J-K, Cho CK, et al. Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer. Tumori. 2009;95(4):449–454.
   PubMed Web of Science ®Google Scholar
• Liu E, Stenmark MH, Schipper MJ, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors. Transl Oncol. 2013;6(4):442–446.
   PubMed Web of Science ®Google Scholar
• McPartlin A, Swaminath A, Wang R, et al. Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases. Int J Radiat Oncol Biol Phys. 2017;99(2):388–395.
   PubMed Web of Science ®Google Scholar
• Méndez Romero A, Keskin-Cambay F, van Os RM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017;22(2):126–131.
   PubMedGoogle Scholar
• Méndez Romero A, Schillemans W, van Os R, et al. The Dutch-Belgian registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases. Int J Radiat Oncol Biol Phys. 2021;109(5):1377–1386.
   Web of Science ®Google Scholar
• Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol. 2006;45(7):831–837.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141(3):543–553.
   PubMed Web of Science ®Google Scholar
• Stintzing S, Grothe A, Hendrich S, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–977.
   PubMed Web of Science ®Google Scholar
• Van De Voorde L, Vanneste B, Houben R, et al. Image-guided stereotactic ablative radiotherapy for the liver: a safe and effective treatment. Eur J Surg Oncol. 2015;41(2):249–256.
   PubMed Web of Science ®Google Scholar
• Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys. 2011;81(3):e39–47.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830–2838.
   PubMed Web of Science ®Google Scholar
• Hong TS, Wo JY, Borger DR, et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. J Natl Cancer Inst. 2017;109(9):1–8.
   Google Scholar
• Jethwa KR, Jang S, Mullikin TC, et al. Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiother Oncol. 2020;146:29–36.
   PubMed Web of Science ®Google Scholar
• Foubert F, Matysiak-Budnik T, Touchefeu Y. Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis. 2014;46(2):105–112.
   PubMedGoogle Scholar
• Ihnát P, Skácelíková E, Vávra P, et al. Novel strategy in the treatment of liver metastases – Hepatic resection combined with stereotactic body radiotherapy. Asian J Surg. 2020;43(9):902–906.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006;45(7):856–864.
   PubMed Web of Science ®Google Scholar
• Grimm J, LaCouture T, Croce R, et al. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys. 2011;12(2):3368.
   PubMed Web of Science ®Google Scholar
• Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–1087.
   PubMed Web of Science ®Google Scholar
• Sahgal A, Chang JH, Ma L, et al. Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2021;110(1):124–136.
   Web of Science ®Google Scholar
• Gkika E, Strouthos I, Kirste S, et al. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol. 2019;195(3):246–253.
   PubMed Web of Science ®Google Scholar
• Owen D, Lukovic J, Hosni A, et al. Challenges in reirradiation of intrahepatic tumors. Semin Radiat Oncol. 2020;30(3):242–252.
   PubMed Web of Science ®Google Scholar
• McDuff SGR, Remillard KA, Zheng H, et al. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018;8(6):414–421.
   PubMed Web of Science ®Google Scholar
• Koong AJ, Toesca DAS, von Eyben R, et al. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Adv Radiat Oncol. 2017;2(1):27–36.
   PubMedGoogle Scholar
• Abusaris H, Hoogeman M, Nuyttens JJ. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. Technol Cancer Res Treat. 2012;11(6):591–597.
   PubMed Web of Science ®Google Scholar
• Fukumitsu N, Okumura T, Takizawa D, et al. Proton beam therapy for metastatic liver tumors. Radiother Oncol. 2015;117(2):322–327.
   PubMed Web of Science ®Google Scholar
• Colbert LE, Cloyd JM, Koay EJ, et al. Proton beam radiation as salvage therapy for bilateral colorectal liver metastases not amenable to second-stage hepatectomy. Surgery. 2017;161(6):1543–1548.
   PubMed Web of Science ®Google Scholar
• Klüter S, Katayama S, Spindeldreier CK, et al. First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany. Strahlenther Onkol. 2020;196(8):691–698.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Henke LE, Shaverdian N, et al. A multi-institutional experience of mr-guided liver stereotactic body radiation therapy. Adv Radiat Oncol. 2019;4(1):142–149.
   PubMedGoogle Scholar
• Vilgrain V, Esvan M, Ronot M, et al. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. Eur Radiol. 2016;26(12):4595–4615.
   PubMed Web of Science ®Google Scholar
• Mittauer K, Paliwal B, Hill P, et al. A new era of image guidance with magnetic resonance-guided radiation therapy for abdominal and thoracic malignancies. Cureus. 2018;10(4):e2422.
   PubMed Web of Science ®Google Scholar
• Hall WA, Paulson ES, van der Heide UA, et al. The transformation of radiation oncology using real-time magnetic resonance guidance: a review. Eur J Cancer. 2019;122:42–52.
   PubMed Web of Science ®Google Scholar